Background Neonatal sepsis is a major cause of morbidity and mortality. It is the third
leading cause of neonatal mortality globally constituting 13% of overall neonatal mortality …

Background Neonatal sepsis is a major cause of morbidity and mortality. It is the third
leading cause of neonatal mortality globally constituting 13% of overall neonatal mortality …

Neonatal Infections are among the most common reasons for admission to the intensive
care unit. Neonatal sepsis (NS) significantly contributes to mortality rates. Empiric antibiotic …

Background Vancomycin is commonly used to treat gram-positive bacterial infections in the
paediatric population, but dosing can be challenging. Population pharmacokinetic (popPK) …

Introduction Vancomycin dosing tailored for newborns is challenging due to the significant
influence of maturation and organ function on pharmacokinetics. Population …

Vancomycin pharmacokinetic/pharmacodynamic (PK/PD) targets have not been validated in
the neonatal population as no specifically designed studies are available. The main goal of …

Background: Vancomycin therapeutic monitoring guidelines were revised in March 2020,
and a population pharmacokinetics-guided Bayesian approach to estimate the 24-hour area …

Abstract Background and Objective Pharmacokinetic models can inform drug dosing of
vancomycin in neonates to optimize therapy. However, the model selected needs to …

Introduction Guidelines for vancomycin therapeutic monitoring recommend using a
Bayesian approach with a population pharmacokinetic model to estimate the 24 h area …

Background Preterms are at risk of systemic infections as the barrier function of their
immature skin is insufficient. The long period of hospitalization and the huge number of …